

Whom It May Concern

Company: KYORIN Holdings, Inc.
 Representative: Yutaka Ogihara
 Representative Director, President
 (Security Code: 4569, TSE Prime)
 Contact: Yoshinori Tanifuji
 Director, Corporate Planning
 Telephone: 03-3525-4707

Revision of Consolidated Financial Forecasts
for Fiscal Year Ended March 31, 2022

TOKYO, Japan (April 26, 2022) –KYORIN Holdings, Inc., today announced that, the Company made the following revisions to the consolidated earnings forecasts for the fiscal year ended March 31, 2022 disclosed on May 11, 2021 (at the time of the financial results announcement) based on the current business performance.

1. Revision of consolidated financial forecasts for fiscal year ended March 31, 2022

(Unit: Millions of yen)

	Net sales	Operating Income	Ordinary income	Net income	Basic earnings per share (yen)
Original forecast (A)	102,600	3,300	3,800	2,700	47.12
Revised forecast (B)	105,500	5,000	5,500	3,800	66.32
Change (B-A)	2,900	1,700	1,700	1,100	—
Change (%)	+2.8	+51.5	+44.7	+40.7	—
(for reference) Results of the previous period	102,904	5,786	6,447	6,130	106.99

2. Reason for revision of consolidated financial forecast

Forecast of consolidated net sales have been revised upward, as sales of long-listing products and generic drugs has exceeded our forecast due to effect by supply shortage triggered by quality violation stemming from several generic companies.

In terms of profits, gross profit increased owing to better than expected sales and SG&A expenses (including R & D expenses) are expected to be in line with forecast, so we have revised operating income, ordinary income and profit attributable to owners of parent upward.

There is no change to the dividend forecast announced on May 11, 2021 (annual dividend of 52 yen per share).

(Note) The above forecasts are based on information that is currently available and actual results may differ materially from those in the forecasts.

Supplementary material

1. About Consolidated Net Sales

unit: ¥ billion

	FY2020(A)	FY2021 (B) (original forecast)	FY2021(C) (revised forecast)	Change (C)–(A)	Change (C)–(B)
Net sales	102.9	102.6	105.5	+2.6	+2.9
New ethical drugs, etc. (Japan)	69.7	68.6	69.7	0	+1.1
New ethical drugs (Overseas)	1.0	0.8	1.0	0	+0.2
Generic drugs	32.2	33.1	34.7	+2.5	+1.6

2. About Main Product Sales

unit: ¥ billion

	FY2020(A)	FY2021(B) (original forecast)	FY2021(C) (revised forecast)	Change (C)–(A)	Change (C)–(B)
New ethical drugs, etc. (Japan)					
Flutiform	13.3	13.9	12.5	−0.8	−1.4
Desalex	5.7	7.2	7.0	+1.3	−0.2
Beova (KYORIN)	7.3	8.6	8.6	+1.3	0
Lasvic	0.9	2.8	1.8	+0.9	−1.0
Pentasa	12.8	11.7	13.9	+1.1	+2.2
Uritos (KYORIN)	2.3	1.0	1.2	−1.1	+0.2
Nasonex	2.8	1.8	2.3	−0.5	+0.5
Kipres	8.3	6.9	8.4	+0.1	+1.5
Mucodyne	3.3	2.9	3.4	+0.1	+0.5
Milton	2.1	2.2	2.0	−0.1	−0.2
Rubysta	2.0	2.1	2.0	0	−0.1
Generic drugs					
MONTELUKAST Tablets “KM” *1	10.8	9.2	12.1	+1.3	+2.9
MOMETASONE Nasal 50 µg “KYORIN” *2	3.8	3.5	3.6	−0.2	+0.1
IMIDAFENACIN tablets & OD “KYORIN” *3	0.7	0.7	0.7	0	0

*1 Authorized generic drug for Kipres

*2 Authorized generic drug for Nasonex

*3 Authorized generic drug for Uritos